Barclays PLC Has $1.01 Million Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Barclays PLC grew its stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 143.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 595,150 shares of the biotechnology company’s stock after purchasing an additional 350,196 shares during the period. Barclays PLC’s holdings in Pacific Biosciences of California were worth $1,011,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in PACB. Atom Investors LP bought a new position in Pacific Biosciences of California in the third quarter worth approximately $30,000. Water Island Capital LLC increased its stake in Pacific Biosciences of California by 91.1% during the 2nd quarter. Water Island Capital LLC now owns 20,000 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 9,537 shares in the last quarter. Atria Investments Inc raised its holdings in Pacific Biosciences of California by 85.7% during the third quarter. Atria Investments Inc now owns 21,968 shares of the biotechnology company’s stock worth $37,000 after buying an additional 10,138 shares during the last quarter. Centiva Capital LP bought a new position in shares of Pacific Biosciences of California in the third quarter valued at $40,000. Finally, Ballentine Partners LLC bought a new position in Pacific Biosciences of California in the 3rd quarter valued at about $43,000.

Analyst Ratings Changes

A number of brokerages have commented on PACB. Piper Sandler boosted their price objective on Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a “neutral” rating in a report on Monday, November 11th. UBS Group lowered Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 price target for the company. in a research report on Monday, November 11th. Scotiabank dropped their price objective on Pacific Biosciences of California from $7.00 to $6.00 and set a “sector outperform” rating on the stock in a research note on Monday, November 11th. Finally, StockNews.com upgraded shares of Pacific Biosciences of California to a “sell” rating in a report on Thursday, January 9th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $2.95.

Insider Activity

In other news, insider Oene Mark Van sold 34,405 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $2.03, for a total transaction of $69,842.15. Following the transaction, the insider now owns 1,597,454 shares of the company’s stock, valued at $3,242,831.62. This represents a 2.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

Pacific Biosciences of California Stock Performance

NASDAQ PACB opened at $1.85 on Wednesday. The company has a market capitalization of $506.65 million, a PE ratio of -1.27 and a beta of 1.95. The company has a debt-to-equity ratio of 1.97, a quick ratio of 8.64 and a current ratio of 9.74. Pacific Biosciences of California, Inc. has a 52-week low of $1.16 and a 52-week high of $7.50. The company has a 50-day simple moving average of $1.98 and a 200 day simple moving average of $1.80.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.